SWP
AQST icon

Stratos Wealth Partners’s Aquestive Therapeutics AQST Stock Holding History

Stratos Wealth Partners’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-73,652
Closed -$476K – 1624
2025
Q4 		$476K Buy
73,652
+652
+0.9% +$4.06K 0.01% 1069
2025
Q3 		$408K Buy
73,000
+23,000
+46% +$99.4K ﹤0.01% 1103
2025
Q2 		$166K Hold
50,000
– – ﹤0.01% 1356
2025
Q1 		$145K Hold
50,000
– – ﹤0.01% 1303
2024
Q4 		$178K Hold
50,000
– – ﹤0.01% 1368
2024
Q3 		$249K Buy
+50,000
New +$195K ﹤0.01% 1234

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Stratos Wealth Partners's AQST Position: Q1 2026 in Review

Stratos Wealth Partners sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 73,652 shares — an estimated $476K sold.

Stratos Wealth Partners first reported a position in AQST in Q3 2024 and held it in 6 quarters. The position peaked at $476K in Q4 2025. 180 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Stratos Wealth Partners reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Stratos Wealth Partners sold 73,652 Aquestive Therapeutics shares in Q1 2026, an estimated $476K.
  • Stratos Wealth Partners first reported a position in Aquestive Therapeutics in Q3 2024 and held it in 6 quarters.
  • Stratos Wealth Partners's Aquestive Therapeutics position peaked at $476K in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Stratos Wealth Partners's 13F filing for Q1 2026, filed 28 Apr 2026.